VVP
MTNB icon

Venture Visionary Partners’s Matinas BioPharma MTNB Stock Holding History

Venture Visionary Partners’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-96
Closed -$3.8K – 1144
2022
Q2 		$3.8K Buy
+96
New +$3.66K ﹤0.01% 1449

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Venture Visionary Partners's MTNB Position: Q3 2022 in Review

Venture Visionary Partners sold out of Matinas BioPharma (MTNB) in Q3 2022, closing a stake of 96 shares — an estimated $3.8K sold.

Venture Visionary Partners first reported a position in MTNB in Q2 2022 and held it in 1 quarter. The position peaked at $3.8K in Q2 2022. 55 funds tracked by Wall St. Rank hold MTNB as of Q3 2022.

  • Venture Visionary Partners reported no remaining Matinas BioPharma position as of Q3 2022 after selling out during the quarter.
  • Venture Visionary Partners sold 96 Matinas BioPharma shares in Q3 2022, an estimated $3.8K.
  • Venture Visionary Partners first reported a position in Matinas BioPharma in Q2 2022 and held it in 1 quarter.
  • Venture Visionary Partners's Matinas BioPharma position peaked at $3.8K in Q2 2022.
  • 55 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2022.

Based on Venture Visionary Partners's 13F filing for Q3 2022, filed 14 Nov 2022.